GLP-1-based therapies and resmetirom operate through distinct and potentially complementary mechanisms: while resmetirom exerts direct hepatic effects by activating THR- to enhance mitochondrial function, reduce hepatic lipogenesis, and promote lipid oxidation specifically in hepatocytes, GLP-1 RAs and multi-agonists address the upstream metabolic drivers of MASLD including insulin resistance, obesity, and systemic inflammation
The latest on the scene: retatrutide , a so-called "triple-agonist" that targets GLP-1, GIP, and glucagon receptors
Most researchers observe that water retention peaks in week 24 and diminishes by 4060% by week 6 without dose modification as the renin-angiotensin-aldosterone system recalibrates
Of all the tissues in your body, your brain is one of the most vulnerable to oxidative stress: its full of unsaturated fats, and it uses a lot of oxygen (20% of your daily oxygen consumption goes to your brain)
Pharmacists may also add in other components, such as vitamin B12, that can change the way the active drug works in the body
Because the results are highly dependant on the patient, we are unable to guarantee a particular outcome
